Correcting calculation and data errors reveals that the original conclusions were incorrect in “The best drug supplement for obesity treatment: a systematic review and network meta-analysis”

Yu, Xiaoxin; Capers, Patrice L.; Zoh, Roger S.; Allison, David B.

doi:10.1186/s13098-023-01134-6

Table 2 Re-extracted information on sex and number of participants alongside data reported in the Salari et al. paper

From: Correcting calculation and data errors reveals that the original conclusions were incorrect in “The best drug supplement for obesity treatment: a systematic review and network meta-analysis”

				Salari Paper Results (N)			New Results^a (N)
Study	Year	Groups (Salari Paper)	Groups (New Results^a)	Total Patients	Men (N)	Women (N)	Total Patients	Men (N)	Women (N)
Apovian [9]	2013	Placebo	Placebo	1496	76	419	1496	76	419
		Naltrexone + bupropion	32 mg/day naltrexone SR + 360 mg/day bupropion SR (NB32)	1496	155	846	1496	155	846
Aronne [10]	2010	Placebo	Placebo	244	13	87	244	8	55
		Pramlintide	Pramlintide (120 µg sc)		12	88		7	54
			Pramlintide (120 µg sc t.i.d.) + sibutramine (10 mg oral q.a.m.)					6	53
			Pramlintide (120 µg sc t.i.d.) + phentermine (37.5 mg oral q.a.m.)					8	53
Davies [17]	2015	Placebo	Placebo	864	97	115	846	97	115
		Liraglutide 0.3 mg	Liraglutide 3.0 mg		220	203		220	203
		Liraglutide 1.8 mg	Liraglutide 1.8 mg		108	103		108	103
Fidler [11]	2011	Placebo	Placebo	4004	353	1248	4004	353	1248
		Lorcaserin 10 mg BID	Lorcaserin 10 mg BID		313	1289		313	1289
		Lorcaserin 10 mg QD	Lorcaserin 10 mg QD		145	656		145	656
Gadde [12]	2011	Placebo	Placebo	2487	299	695	2487	299	695
		Phentermine 7.5 mg + topiramate 46.0 mg	Phentermine 7.5 mg + topiramate 46.0 mg		149	349		149	349
		Phentermine 15.0 mg + topiramate 92.0 mg	Phentermine 15.0 mg + topiramate 92.0 mg		302	693		302	693
Greenway [8]	2010	Placebo	Placebo	1742	85	496	1742	85	496
		Naltrexone + bupropion 16.0 mg	Naltrexone16.0 mg + bupropion		88	490		88	490
		Naltrexone + bupropion 32.0 mg	Naltrexone32.0 mg + bupropion		87	496		87	496
Le Roux [13]	2017	Placebo	Placebo	2254	176	573	2254	176	573
		Liraglutide	Liraglutide 3.0 mg	2254	364	1141	2254	364	1141
Lu [14]	2018	Placebo	Placebo	171	28	57	170	28	57
		Lorcaserin	Lorcaserin 10.0 mg	171	39	46	170	39	46
O’Neil [15]	2012	Placebo	Placebo	508	73	84	603	115	137
		Orlistat 120.0 mg BID	Lorcaserin 10 mg BID		86	83		119	137
		Orlistat 120.0 mg QD	Lorcaserin 10 mg QD		34	41		42	53
Pi-Sunyer [16]	2015	Placebo	Placebo	3731	273	971	3731	273	971
		Liraglutide	Liraglutide 3.0 mg QD	3731	530	1957	3731	530	1957
Smith [17]	2010	Placebo	Placebo	3182	253	1331	3182	253	1331
		Lorcaserin	Lorcaserin 10.0 mg	3182	272	1321	3182	272	1321

Abbreviations: BID, twice a day; q.a.m., every morning; QD, every day; sc, subcutaneous; t.i.d., three times a day
The difference between our extraction and original study used underlining
a: “New” results are from our data extraction from the original studies. Underlining denotes discrepant values

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diabetology & Metabolic Syndrome

Contact us